



ASX ANNOUNCEMENT

14 November 2017

COLLABORATION AGREEMENT SIGNED WITH MMJ PHYTOTECH, HARVEST ONE CANNABIS & SOPHISTICATED INVESTOR PLACEMENT

- Heavily over-subscribed sophisticated investor placement of ~A\$1.62m
- Strategic Investment of A\$500,000 from MMJ Phytotech Ltd (ASX:MMJ)
- Collaboration agreement with MMJ and Harvest One Cannabis Inc.

Life sciences company **eSense-Lab Ltd (“eSense” or the “Company”)**, (ASX:ESE), is pleased to advise that it has received binding commitments from professional and sophisticated investors for a placement of A\$1,619,500, which will be completed by way of the issue of 6,478,000 CHESSE Depository Interests (CDIs) over fully paid ordinary shares in the Company (Shares) at \$0.25 per CDI (“Placement”). Each CDI will represent one underlying Share.

In addition, the Company has received a binding commitment from MMJ Phytotech Ltd (ASX: MMJ) for a strategic investment of A\$500,000, which will be completed by way of the issue of 2,500,000 CDI’s at \$0.20 per CDI (“Strategic Investment”). MMJ will receive 1 free option for every 2 CDI’s issued, at a \$0.30 exercise and expiry date of 3 years from date of issue, subject to shareholder approval.

The total capital raising commitments is A\$2,119,500. The Placement received significant interest and was substantially oversubscribed.

The CDI’s to be issued in respect of the Placement and Strategic Investment will be issued within the Company’s existing ASX Listing Rule 7.1 placement capacity.

Otsana Capital acted as lead manager for the Placement and the Strategic Investment, and will receive a lead manager fee of 5m unlisted options with an exercise price of \$0.40 and expiry date 2 years from date of issue, subject to shareholder approval.

Collaboration Agreement

Under the terms of the strategic investment, MMJ Phytotech Limited (ASX:MMJ) and Harvest One Cannabis Inc. (TSXV: HVST) have signed a Collaboration Agreement with eSense, for the purposes of developing new intellectual property and products specific to the recreational and medical cannabis markets, as well as utilizing each Company’s respective intellectual property and technologies to further enhance their existing technologies and product offerings.



About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX. MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through its ~59% interest in TSX-V listed **Harvest One Cannabis Inc** (TSXV: HVST) and its 100% interest in Israeli research and development subsidiary, **PhytoTech Therapeutics Ltd**, both of which are strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

About Harvest One Cannabis Inc.

Harvest One Cannabis Inc. (TSXV: HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.

This announcement brings the Company out of trading halt.

Ends

About eSense-Lab

eSense-Lab (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.



To learn more about eSense – Lab, visit www.esense-lab.com

Corporate Advisors

Otsana Capital

108 Outram Street

West Perth WA 6005

Telephone: +61 8 9486 7244

www.otsana.com